drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Chimeric anti-CD20 monoclonal antibody that depletes CD20+ B cells to reduce pathogenic autoantibodies and immune-driven neuroinflammation; used here to mitigate antibody-mediated disruption of NMDA receptor signaling. Adult dose 1 g or pediatric 375 mg/m2, repeated after ~14 days.
nci_thesaurus_concept_id
C1702
nci_thesaurus_preferred_term
Rituximab
nci_thesaurus_definition
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
drug_mesh_term
Rituximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Other treatment
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them via Fc-mediated ADCC, complement-dependent cytotoxicity, and apoptosis, reducing pathogenic autoantibody production and immune-driven inflammation (e.g., NMDA receptor autoimmunity).
drug_name
Rituximab
nct_id_drug_ref
NCT05946486